PMEL and neoplasm: Clinical studies investigating new treatment options as, e.g., tebentafusp (IMCgp100), a bispecific protein bridging CD3 +  T cells and gp100-expressing tumor cells (Liddy et al. 2012) have shown promising results in phase I/II trials so far (Carvajal et al. 2018; Middleton et al. 2016).